Search the Newsreel

CVRx (NASDAQ: CVRX) grows Q2 2026 revenue but cuts outlook

CVRx, Inc. reported a 16% increase in Q2 2026 revenue to $15.7 million, primarily driven by U.S. heart failure sales, with gross profit rising to $13.7 million and gross margin improving to 87%. Despite this growth, the company posted a net loss of $14.0 …

CVRx Reports Second Quarter 2026 Financial and Operating Results

CVRx, Inc. announced its Q2 2026 financial results, reporting $15.7 million in total revenue, a 16% increase year-over-year, and a gross margin of 87%. Despite strong growth and a new Medicare Advantage coverage policy from Humana for its Barostim therapy, the company updated its …

Compared to Estimates, CVRx (CVRX) Q2 Earnings: A Look at Key Metrics

CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates

Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14

Lake Street has reaffirmed its Buy rating for CVRx Inc (CVRX.US) and maintained its target price at $14. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

CVRx Inc (CVRX) Institutional Confidence

The article details the institutional confidence in CVRx Inc (CVRX), noting its current institutional shareholding score of 5.00, which ranks 107th in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion stands at 65.53%, a decrease of 19.00% quarter-over-quarter. Bill Nygren (OAKMX) is highlighted …

CVRx to Present at Canaccord Genuity’s 46th Annual Growth Conference

CVRx, Inc., a medical device company focused on neuromodulation solutions for cardiovascular diseases, announced its management team will present at Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026, at 1:00 p.m. ET. The presentation will discuss the company's Barostim technology, the first …

CVRx presentation will stream live from Boston on Aug. 11

CVRx (NASDAQ: CVRX), a medical device company specializing in neuromodulation therapies for cardiovascular disease, announced that its management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 1:00 p.m. ET. A live webcast and archived replay …

CVRx Inc (CVRX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of CVRx Inc (CVRX), outlining its major shareholders by proportion, including venture capital firms, investment advisors, and corporate entities like Johnson & Johnson Innovation-JJDC, Inc. It also presents institutional shareholding data over several quarters and lists related ETFs …

CVRx Inc (CVRX) Balance Sheet

This article provides a detailed balance sheet for CVRx Inc (CVRX), presenting quarterly and annual financial data spanning several years. It includes key metrics such as cash and short-term investments, receivables, inventory, total assets, various liabilities, and shareholders' equity. The data allows for analysis …

CVRX|CVRx Inc|Price:4.750|Chg%:-0.140

CVRx Inc (CVRX) is a medical device company focused on neuromodulation solutions for cardiovascular diseases, whose stock is currently priced at $4.740, down 3.07%. Despite healthy fundamentals, significant growth potential, and a "Buy" rating from analysts with a target price of $12.20, its valuation …

CVRx Inc CVRX Cash Flow Statement

This article provides a comprehensive quarterly cash flow statement for CVRx Inc (CVRX), detailing operating, investing, and financing cash flows from Q1 2020 to Q1 2026. It includes year-over-year percentage changes and absolute values for various cash flow components, alongside FAQs explaining key cash …

CVRx (CVRX) Q4 2025 earnings summary

CVRx reported Q4 2025 revenue of $16 million, marking a 4% year-over-year increase, with full-year revenue reaching $56.7 million. The company expanded its U.S. implanting centers and initiated the BENEFIT-HF trial to potentially triple its addressable market. Gross profit improved to 86%, while the …

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

CVRx, Inc. (NASDAQ: CVRX) announced it will release its second quarter 2026 financial and operating results after market close on Thursday, August 6, 2026. The company will host a conference call on the same day at 4:30 p.m. Eastern Time to discuss the results, …

CVRx Plans Aug. 6 Webcast on Second-Quarter Results

CVRx (NASDAQ: CVRX) announced it will release its second-quarter 2026 financial and operating results after market close on Thursday, August 6, 2026. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time to review the results. Historically, previous earnings-date …

CVRx (CVRX) Proxy filing Summary

CVRx (CVRX) has released its proxy filing summary for the annual meeting scheduled for June 1, 2026. Stockholders will vote on the election of three Class II directors and the ratification of Grant Thornton LLP as the independent auditor for 2026. The company remains …

Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating

Craig-Hallum has reiterated its Buy rating on CVRx Inc (CVRX.US). The firm maintains a positive outlook on the company.

CVRx (CVRX) The 44th Annual William Blair Growth Stock Conference Summary

CVRx presented at the 44th Annual William Blair Growth Stock Conference, highlighting its new CEO's strategic focus on market development and therapy awareness. The company emphasized the significant market opportunity for its Barostim therapy, a unique neuromodulation treatment for heart failure with robust clinical …

(CVRX) Risk Channels and Responsive Allocation

This article analyzes Cvrx Inc. (CVRX) using AI models to identify risk channels and responsive allocation strategies. It highlights a positive near-term sentiment that may shift and a critical 178.0:1 risk-reward setup. The analysis provides key findings, multi-timeframe signal analysis, and institutional trading strategies …

Analysts Have Made A Financial Statement On CVRx, Inc.'s (NASDAQ:CVRX) First-Quarter Report

CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates